Monday morning, 8:47 AM. The post-PoC commercial planning meeting closed at 8:00. The trial data is strong. The commercialization strategy is six months behind where it should be. The Series C anchor investor is asking pointed questions.
Life sciences operators in South San Francisco move from clinical milestones to commercial milestones at a specific cadence. The strategy work needs to ship before the milestone, not after.
By 9:03 the chief commercial officer asks the recurring question. What is our commercial-translation document, and where does it live.
Most life sciences teams have a clinical narrative and a slide deck. Neither is the document.
South San Francisco biotech operators at post-PoC valuation face this most acutely. The Series C investor expects commercial readiness in writing.
The Strategy Diagnostic produces the commercial-translation document. 10 business days. $5,000 flat. Output covers positioning across clinical and commercial registers, ICP architecture by buyer type (KOL, payer, prescriber), commercial sequencing by stage, and the 90-day priority roadmap.
For life sciences operators with a focused single-decision question (payer evidence positioning, KOL engagement strategy, launch sequencing), the Strategic Intervention at $5,000-$15,000 sizes the work to scope.
Both engagements work alongside existing scientific PR, KOL outreach, and regulatory teams. The diagnostic produces the spine; the specialist functions execute the muscle.
Yes. Life sciences operators face specific commercial-translation patterns: clinical-to-commercial bridging, payer evidence positioning, KOL engagement, launch sequencing. The diagnostic addresses each.
Yes. South San Francisco signals biotech-grade operating altitude. Global pharma reads it as production-grade scientific credibility. Geography is bonus signal.
Life sciences PR amplifies milestone news. The diagnostic builds the commercial-translation frame those milestones land into. Different jobs. Often used together.
Strategy Diagnostic $5,000. Positioning Sprint $7,500. Paid Media Audit $2,500. Conversion Review $3,500. Marketing Partnership $4,500/month. AI Visibility Audit $2,500.
Most agencies in the corridor specialize in scientific PR or KOL engagement. The diagnostic produces the commercial-translation document those teams execute against.
Yes. Pre-launch commercial planning is one of the highest-leverage moments. NDA signed before any diagnostic work. Confidentiality is a default.
Commercial-translation strategy for clinical-to-commercial transition.
Read the gate →Category narrative across clinical, payer, and prescriber buyers.
Read the gate →Answer-engine query coverage for therapeutic category claims.
Read the gate →Anonymized case template. Industry, stage, scope, 90-day result framing. To be filled when client cases are approved for publication.
Anonymized case template. Industry, stage, scope, 90-day result framing. To be filled when client cases are approved for publication.
Anonymized case template. Industry, stage, scope, 90-day result framing. To be filled when client cases are approved for publication.
Clinical milestones are the foundation. Commercial readiness is what the next investor reads.
Start with the Strategy Diagnostic · $5,000 →